Reports on Acute Myeloid Leukemia Findings from Institute of Biomedical Chemistry Provide New Insights (Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia).

New research from the Institute of Biomedical Chemistry in Moscow, Russia suggests that combining new therapeutics with all-trans-retinoic acid (ATRA) could improve the effectiveness of acute myeloid leukemia (AML) treatment. The study used transcriptomic profiling to identify key targets that can enhance the therapeutic effect of ATRA. The researchers found that cyclin-dependent kinase 6 (CDK6), tumor necrosis factor alpha (TNF-alpha), and transcriptional repressor CUX1 were key regulators of the molecular response to ATRA treatment in different cell lines. The study also proposed that combining ATRA with a CDK6 inhibitor (palbociclib) could be an alternative approach for AML treatment. [Extracted from the article]